MedTrace Logo

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC

NCT04631770 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1362

Last updated 2023-09-28

No results posted yet for this study

Summary

Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung nodules are pure ground-glass or part-solid nodules. Non-solid nodules rarely develop mediastinal lymph node metastasis. The present study is a prospective, multicenter and randomized clinical trial, comparing the overall survival and disease-free survival of whether performing mediastinal lymph node dissection in non-small cell lung cancer with ground-glass nodule CT features.

Conditions

  • Lung Neoplasms
  • Lymph Node Excision

Interventions

PROCEDURE

Systemic mediastinal lymph node dissection

Systematic hilar and mediastinal lymph node dissection.

PROCEDURE

Spared mediastinal lymph node dissection

Mediastinal lymph node is spared in this group.

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Zhenfa Zhenfa, MD · Tianjin Medical University Cancer Institute and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2024-05-01
Completion
2029-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04631770 on ClinicalTrials.gov